卜亚洲



英夫利西单抗辅助治疗克罗恩病伴不全性肠梗阻患者的疗效及安全性分析

卜亚洲

【摘要】目的 研究英夫利西单抗辅助治疗克罗恩病伴不全性肠梗阻患者的疗效及安全性。方法 将我院接收的48例克罗恩病伴不全性肠梗阻患者作为研究对象，随机分为对照组和观察组，各24例。对照组采用常规治疗方法，观察组在常规治疗基础上给予英夫利西单抗治疗。观察两组患者临床疗效及不良反应发生情况。结果 对照组患者的临床疗效低于观察组，差异具有统计学意义（P＜0．05）；对照组患者不良反应发生率低于观察组，差异具有统计学意义（P＜0．05）。结论 临床治疗克罗恩病伴不全性肠梗阻患者时，在常规治疗基础上，采用英夫利西单抗治疗，可缓解患者肠梗阻症状，但须及时处理英夫利西单抗引起的不良反应。

【关键词】英夫利西单抗；辅助；克罗恩病；肠梗阻

Objective Study infliximab for adjuvant treatment of Crohn's disease in patients with incomplete intestinal obstruction，and to analyze the efficacy and safety． Methods 48 patients with Crohn's disease with incomplete intestinal obstruction as the object of study patients in our hospital，were randomly divided into two groups，24 cases in each． Control group used routine treatment，observation group on the basis of routine treatment for infliximab therapy． The clinical efficacy and adverse reactions of the two groups were observed． Results The clinical curative effect of the control group was lower than that of the observation group， the difference was statistically significant（P＜0．05）． The incidence of adverse reactions in the control group was significantly lower than that in the observation group，the difference was statistically significant（P＜0．05）． Conclusion Clinical treatment of Crohn's disease in patients with incomplete intestinal obstruction，in the conventional treatment based on the use of infliximab therapy can relieve symptoms in patients with intestinal obstruction，But the adverse reactions caused by infliximab shall be handled in a timely manner．

【Key words】Infliximab，Auxiliary，Crohn's disease，Bowel obstruction

我国克罗恩病伴不全性肠梗阻发病率日益上升，反复发作，是一种原因不明的炎症性肠病［1］。克罗恩病伴不全性肠梗阻采用传统药物治疗，效果不理想［2］。有研究表明［3］，使用英夫利西单抗辅助治疗，临床效果较好。本研究分析英夫利西单抗辅助治疗克罗恩病伴不全性肠梗阻患者的疗效，其结果如下。

1 资料与方法

1.1 基本资料

将我院2014年8月～2015年7月接收的48例克罗恩病伴不全性肠梗阻患者为对象研究，随机分为对照组和观察组，各24例。对照组男12例，女12例；年龄22～62岁，平均年龄（41.2±6.1）岁。观察组男14例，女10例；年龄23～61岁，平均年龄（40.3±4.2）岁。……